{
    "abstract": "In response to global interest in the development of a universal influenza vaccine, the Bill & Melinda Gates Foundation, PATH, and the Global Funders Consortium for Universal Influenza Vaccine Development convened a meeting of experts (London, UK, May 2018) to assess the role of a standardized controlled human influenza virus infection model (CHIVIM) towards the development of novel influenza vaccine candidates. This report (in two parts) summarizes those discussions and offers consensus recommendations. Part 1 covers challenge virus selection, regulatory and ethical considerations, and issues concerning standardization, access, and capacity. This article (Part 2) summarizes the discussion and recommendations concerning CHIVIM methods. The panelists identified an overall need for increased standardization of CHIVIM trials, in order to produce comparable results that can support universal vaccine licensure. Areas of discussion included study participant selection and screening, route of exposure and dose, devices for administering challenge, rescue therapy, protection of participants and institutions, clinical outcome measures, and other considerations. The panelists agreed upon specific recommendations to improve the standardization and usefulness of the model for vaccine development. Experts agreed that a research network of institutions working with a standardized CHIVIM could contribute important data to support more rapid development and licensure of novel vaccines capable of providing long-lasting protection against seasonal and pandemic influenza strains.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Stanley A.",
                    "initial": "S.A.",
                    "last": "Plotkin"
                },
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Gilbert"
                }
            ],
            "doi": "10.1093/cid/cis238",
            "firstpage": "1615",
            "issn": "10584838",
            "lastpage": "1617",
            "pmid": "22437237",
            "pub_year": 2012,
            "title": "Nomenclature for immune correlates of protection after vaccination",
            "volume": "54"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Bruce L.",
                    "initial": "B.L.",
                    "last": "Innis"
                },
                {
                    "first": "Francesco",
                    "initial": "F.",
                    "last": "Berlanda Scorza"
                },
                {
                    "first": "Jeremy S.",
                    "initial": "J.S.",
                    "last": "Blum"
                },
                {
                    "first": "Varsha K.",
                    "initial": "V.K.",
                    "last": "Jain"
                },
                {
                    "first": "Anastazia",
                    "initial": "A.",
                    "last": "Older Aguilar"
                },
                {
                    "first": "Diane J.",
                    "initial": "D.J.",
                    "last": "Post"
                },
                {
                    "first": "Paul C.",
                    "initial": "P.C.",
                    "last": "Roberts"
                },
                {
                    "first": "Niteen",
                    "initial": "N.",
                    "last": "Wairagkar"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "White"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Bresee"
                }
            ],
            "doi": "10.1016/j.vaccine.2019.06.080",
            "firstpage": "4823",
            "issn": "0264410X",
            "lastpage": "4829",
            "pmid": "31362819",
            "pub_year": 2019,
            "title": "Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity",
            "volume": "37"
        },
        "b0015": null,
        "b0020": null,
        "b0025": {
            "authors": [
                {
                    "first": "John W.",
                    "initial": "J.W.",
                    "last": "Little"
                },
                {
                    "first": "R. Douglas",
                    "initial": "R.D.",
                    "last": "Gordon"
                },
                {
                    "first": "William J.",
                    "initial": "W.J.",
                    "last": "Hall"
                },
                {
                    "first": "Frieda K.",
                    "initial": "F.K.",
                    "last": "Roth"
                }
            ],
            "doi": "10.1002/jmv.1890030303",
            "firstpage": "177",
            "issn": "01466615",
            "lastpage": "188",
            "pmid": "479857",
            "pub_year": 1979,
            "title": "Attenuated influenza produced by experimental intranasal inoculation",
            "volume": "3"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Carrat"
                },
                {
                    "first": "Elisabeta",
                    "initial": "E.",
                    "last": "Vergu"
                },
                {
                    "first": "Neil M.",
                    "initial": "N.M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Lemaitre"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Cauchemez"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Leach"
                },
                {
                    "first": "Alain Jacques",
                    "initial": "A.J.",
                    "last": "Valleron"
                }
            ],
            "doi": "10.1093/aje/kwm375",
            "firstpage": "775",
            "issn": "00029262",
            "lastpage": "785",
            "pmid": "18230677",
            "pub_year": 2008,
            "title": "Time lines of infection and disease in human influenza: A review of volunteer challenge studies",
            "volume": "167"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Shobana",
                    "initial": "S.",
                    "last": "Balasingam"
                },
                {
                    "first": "Annelies",
                    "initial": "A.",
                    "last": "Wilder-Smith"
                }
            ],
            "doi": "10.1016/j.ijid.2016.05.013",
            "firstpage": "18",
            "issn": "12019712",
            "lastpage": "29",
            "pmid": "27208631",
            "pub_year": 2016,
            "title": "Randomized controlled trials for influenza drugs and vaccines: A review of controlled human infection studies",
            "volume": "49"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Ding Y.",
                    "initial": "D.Y.",
                    "last": "Oh"
                },
                {
                    "first": "Aeron C.",
                    "initial": "A.C.",
                    "last": "Hurt"
                }
            ],
            "doi": "10.3389/fmicb.2016.00080",
            "issn": "1664302X",
            "pub_year": 2016,
            "title": "Using the ferret as an animal model for investigating influenza antiviral effectiveness",
            "volume": "7"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Amy Caryn",
                    "initial": "A.C.",
                    "last": "Sherman"
                },
                {
                    "first": "Aneesh",
                    "initial": "A.",
                    "last": "Mehta"
                },
                {
                    "first": "Neal W.",
                    "initial": "N.W.",
                    "last": "Dickert"
                },
                {
                    "first": "Evan J.",
                    "initial": "E.J.",
                    "last": "Anderson"
                },
                {
                    "first": "Nadine",
                    "initial": "N.",
                    "last": "Rouphael"
                }
            ],
            "doi": "10.3389/fcimb.2019.00107",
            "issn": "22352988",
            "pmid": "31065546",
            "pub_year": 2019,
            "title": "The future of flu: A review of the human challenge model and systems biology for advancement of influenza vaccinology",
            "volume": "9"
        },
        "b0050": {
            "authors": [
                {
                    "first": "John S.",
                    "initial": "J.S.",
                    "last": "Oxford"
                },
                {
                    "first": "Juliette R.",
                    "initial": "J.R.",
                    "last": "Oxford"
                }
            ],
            "doi": "10.1586/erv.12.77",
            "firstpage": "929",
            "issn": "14760584",
            "lastpage": "937",
            "pmid": "23002974",
            "pub_year": 2012,
            "title": "Clinical, scientific and ethnographic studies of influenza in quarantine",
            "volume": "11"
        },
        "b0055": {
            "authors": [
                {
                    "first": "FY",
                    "initial": "F.",
                    "last": "Aoki"
                },
                {
                    "first": "JC",
                    "initial": "J.",
                    "last": "Crowley"
                }
            ],
            "doi": "10.1111/j.1365-2125.1976.tb00640.x",
            "firstpage": "869",
            "issn": "03065251",
            "lastpage": "878",
            "pmid": "973982",
            "pub_year": 1976,
            "title": "Distribution and removal of human serum albumin\u2010technetium 99m instilled intranasally.",
            "volume": "3"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Alford"
                },
                {
                    "first": "Julius A.",
                    "initial": "J.A.",
                    "last": "Kasel"
                },
                {
                    "first": "Peter J.",
                    "initial": "P.J.",
                    "last": "Gerone"
                },
                {
                    "first": "Vernon",
                    "initial": "V.",
                    "last": "Knight"
                }
            ],
            "doi": "10.3181/00379727-122-31255",
            "firstpage": "800",
            "issn": "00379727",
            "lastpage": "804",
            "pmid": "5918954",
            "pub_year": 1966,
            "title": "Human Influenza Resulting from Aerosol Inhalation",
            "volume": "122"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                },
                {
                    "first": "R. Gordon",
                    "initial": "R.G.",
                    "last": "Douglas"
                },
                {
                    "first": "David S.",
                    "initial": "D.S.",
                    "last": "Fedson"
                },
                {
                    "first": "Julius A.",
                    "initial": "J.A.",
                    "last": "Kasel"
                }
            ],
            "doi": "10.1093/infdis/124.5.473",
            "firstpage": "473",
            "issn": "00221899",
            "lastpage": "480",
            "pmid": "5000515",
            "pub_year": 1971,
            "title": "Correlated studies of a recombinant influenza-virus vaccine. Iii. protection against experimental influenza in man",
            "volume": "124"
        },
        "b0070": {
            "authors": [
                {
                    "first": "P. S.",
                    "initial": "P.S.",
                    "last": "Hasleton"
                }
            ],
            "firstpage": "391",
            "issn": "00218782",
            "lastpage": "400",
            "pmid": "4564685",
            "pub_year": 1972,
            "title": "The internal surface area of the adult human lung.",
            "volume": "112"
        },
        "b0075": null,
        "b0080": {
            "authors": [
                {
                    "first": "Takahide",
                    "initial": "T.",
                    "last": "Ito"
                },
                {
                    "first": "Kanako",
                    "initial": "K.",
                    "last": "Akamatsu"
                },
                {
                    "first": "Akira",
                    "initial": "A.",
                    "last": "Ukimura"
                },
                {
                    "first": "Tomohiro",
                    "initial": "T.",
                    "last": "Fujisaka"
                },
                {
                    "first": "Michishige",
                    "initial": "M.",
                    "last": "Ozeki"
                },
                {
                    "first": "Yumiko",
                    "initial": "Y.",
                    "last": "Kanzaki"
                },
                {
                    "first": "Nobukazu",
                    "initial": "N.",
                    "last": "Ishizaka"
                }
            ],
            "doi": "10.2169/internalmedicine.0316-17",
            "firstpage": "1819",
            "issn": "09182918",
            "lastpage": "1826",
            "pmid": "29491280",
            "pub_year": 2018,
            "title": "The prevalence and findings of subclinical influenza-associated cardiac abnormalities among japanese patients",
            "volume": "57"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Frederick G.",
                    "initial": "F.G.",
                    "last": "Hayden"
                },
                {
                    "first": "Norio",
                    "initial": "N.",
                    "last": "Sugaya"
                },
                {
                    "first": "Nobuo",
                    "initial": "N.",
                    "last": "Hirotsu"
                },
                {
                    "first": "Nelson",
                    "initial": "N.",
                    "last": "Lee"
                },
                {
                    "first": "Menno D.",
                    "initial": "M.D.",
                    "last": "De Jong"
                },
                {
                    "first": "Aeron C.",
                    "initial": "A.C.",
                    "last": "Hurt"
                },
                {
                    "first": "Tadashi",
                    "initial": "T.",
                    "last": "Ishida"
                },
                {
                    "first": "Hisakuni",
                    "initial": "H.",
                    "last": "Sekino"
                },
                {
                    "first": "Kota",
                    "initial": "K.",
                    "last": "Yamada"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Portsmouth"
                },
                {
                    "first": "Keiko",
                    "initial": "K.",
                    "last": "Kawaguchi"
                },
                {
                    "first": "Takao",
                    "initial": "T.",
                    "last": "Shishido"
                },
                {
                    "first": "Masatsugu",
                    "initial": "M.",
                    "last": "Arai"
                },
                {
                    "first": "Kenji",
                    "initial": "K.",
                    "last": "Tsuchiya"
                },
                {
                    "first": "Takeki",
                    "initial": "T.",
                    "last": "Uehara"
                },
                {
                    "first": "Akira",
                    "initial": "A.",
                    "last": "Watanabe"
                }
            ],
            "doi": "10.1056/NEJMoa1716197",
            "firstpage": "913",
            "issn": "00284793",
            "lastpage": "923",
            "pmid": "30184455",
            "pub_year": 2018,
            "title": "Baloxavir marboxil for uncomplicated influenza in adults and adolescents",
            "volume": "379"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Frederick G.",
                    "initial": "F.G.",
                    "last": "Hayden"
                },
                {
                    "first": "Nahoko",
                    "initial": "N.",
                    "last": "Shindo"
                }
            ],
            "doi": "10.1097/QCO.0000000000000532",
            "firstpage": "176",
            "issn": "09517375",
            "lastpage": "186",
            "pmid": "30724789",
            "pub_year": 2019,
            "title": "Influenza virus polymerase inhibitors in clinical development",
            "volume": "32"
        },
        "b0095": null,
        "b0100": {
            "authors": [
                {
                    "first": "Joanna",
                    "initial": "J.",
                    "last": "Dobson"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Whitley"
                },
                {
                    "first": "Stuart",
                    "initial": "S.",
                    "last": "Pocock"
                },
                {
                    "first": "Arnold S.",
                    "initial": "A.S.",
                    "last": "Monto"
                }
            ],
            "doi": "10.1016/S0140-6736(14)62449-1",
            "firstpage": "1729",
            "issn": "01406736",
            "lastpage": "1737",
            "pmid": "25640810",
            "pub_year": 2015,
            "title": "Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials",
            "volume": "385"
        },
        "b0105": null,
        "b0110": {
            "authors": [
                {
                    "first": "Sudhir",
                    "initial": "S.",
                    "last": "Venkatesan"
                },
                {
                    "first": "Puja R.",
                    "initial": "P.R.",
                    "last": "Myles"
                },
                {
                    "first": "Jo",
                    "initial": "J.",
                    "last": "Leonardi-Bee"
                },
                {
                    "first": "Stella G.",
                    "initial": "S.G.",
                    "last": "Muthuri"
                },
                {
                    "first": "Malak",
                    "initial": "M.",
                    "last": "Al Masri"
                },
                {
                    "first": "Nick",
                    "initial": "N.",
                    "last": "Andrews"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Bantar"
                },
                {
                    "first": "Gal",
                    "initial": "G.",
                    "last": "Dubnov-Raz"
                },
                {
                    "first": "Patrick",
                    "initial": "P.",
                    "last": "Grardin"
                },
                {
                    "first": "Evelyn S.C.",
                    "initial": "E.S.C.",
                    "last": "Koay"
                },
                {
                    "first": "Tze Ping",
                    "initial": "T.P.",
                    "last": "Loh"
                },
                {
                    "first": "Ziad",
                    "initial": "Z.",
                    "last": "Memish"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Maria E.",
                    "initial": "M.E.",
                    "last": "Oliva"
                },
                {
                    "first": "Barbara A.",
                    "initial": "B.A.",
                    "last": "Rath"
                },
                {
                    "first": "Brunhilde",
                    "initial": "B.",
                    "last": "Schweiger"
                },
                {
                    "first": "Julian W.",
                    "initial": "J.W.",
                    "last": "Tang"
                },
                {
                    "first": "Dat",
                    "initial": "D.",
                    "last": "Tran"
                },
                {
                    "first": "Tjasa",
                    "initial": "T.",
                    "last": "Vidmar"
                },
                {
                    "first": "Pauline A.",
                    "initial": "P.A.",
                    "last": "Waight"
                },
                {
                    "first": "Jonathan S.",
                    "initial": "J.S.",
                    "last": "Nguyen-Van-Tam"
                }
            ],
            "doi": "10.1093/cid/cix127",
            "firstpage": "1328",
            "issn": "10584838",
            "lastpage": "1334",
            "pmid": "28199524",
            "pub_year": 2017,
            "title": "Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected with Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis",
            "volume": "64"
        },
        "b0115": {
            "authors": [
                {
                    "first": "John H.",
                    "initial": "J.H.",
                    "last": "Beigel"
                },
                {
                    "first": "Pablo",
                    "initial": "P.",
                    "last": "Tebas"
                },
                {
                    "first": "Marie Carmelle",
                    "initial": "M.C.",
                    "last": "Elie-Turenne"
                },
                {
                    "first": "Ednan",
                    "initial": "E.",
                    "last": "Bajwa"
                },
                {
                    "first": "Todd E.",
                    "initial": "T.E.",
                    "last": "Bell"
                },
                {
                    "first": "Charles B.",
                    "initial": "C.B.",
                    "last": "Cairns"
                },
                {
                    "first": "Shmuel",
                    "initial": "S.",
                    "last": "Shoham"
                },
                {
                    "first": "Jaime G.",
                    "initial": "J.G.",
                    "last": "Deville"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Feucht"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Feinberg"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Luke"
                },
                {
                    "first": "Kanakatte",
                    "initial": "K.",
                    "last": "Raviprakash"
                },
                {
                    "first": "Janine",
                    "initial": "J.",
                    "last": "Danko"
                },
                {
                    "first": "Dorothy",
                    "initial": "D.",
                    "last": "O'Neil"
                },
                {
                    "first": "Julia A.",
                    "initial": "J.A.",
                    "last": "Metcalf"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "King"
                },
                {
                    "first": "Timothy H.",
                    "initial": "T.H.",
                    "last": "Burgess"
                },
                {
                    "first": "Evgenia",
                    "initial": "E.",
                    "last": "Aga"
                },
                {
                    "first": "H. Clifford",
                    "initial": "H.C.",
                    "last": "Lane"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Hughes"
                },
                {
                    "first": "Richard T.",
                    "initial": "R.T.",
                    "last": "Davey"
                },
                {
                    "first": "Pablo",
                    "initial": "P.",
                    "last": "Tebas"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Quinn"
                },
                {
                    "first": "Yan",
                    "initial": "Y.",
                    "last": "Jiang"
                },
                {
                    "first": "Marie Carmelle",
                    "initial": "M.C.",
                    "last": "Elie-Turenne"
                },
                {
                    "first": "Robyn",
                    "initial": "R.",
                    "last": "Hoelle"
                },
                {
                    "first": "Nicole",
                    "initial": "N.",
                    "last": "Iovine"
                },
                {
                    "first": "Robert Shawn",
                    "initial": "R.S.",
                    "last": "Wills"
                },
                {
                    "first": "Socorro",
                    "initial": "S.",
                    "last": "Pata"
                },
                {
                    "first": "Monique",
                    "initial": "M.",
                    "last": "Huggins"
                },
                {
                    "first": "Belinda",
                    "initial": "B.",
                    "last": "Manukian"
                },
                {
                    "first": "Ednan",
                    "initial": "E.",
                    "last": "Bajwa"
                },
                {
                    "first": "Carrie",
                    "initial": "C.",
                    "last": "Holland"
                },
                {
                    "first": "Kelsey",
                    "initial": "K.",
                    "last": "Brait"
                },
                {
                    "first": "Taylor",
                    "initial": "T.",
                    "last": "Hunt"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Stowell"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Slater"
                },
                {
                    "first": "Todd E.",
                    "initial": "T.E.",
                    "last": "Bell"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Townsends"
                },
                {
                    "first": "Charles B.",
                    "initial": "C.B.",
                    "last": "Cairns"
                },
                {
                    "first": "Eugenia B.",
                    "initial": "E.B.",
                    "last": "Quackenbush"
                },
                {
                    "first": "Yara A.",
                    "initial": "Y.A.",
                    "last": "Park"
                },
                {
                    "first": "Paul Gaither",
                    "initial": "P.G.",
                    "last": "Jordan"
                },
                {
                    "first": "Cherie",
                    "initial": "C.",
                    "last": "Blanchet"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Chronowski"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Alvarez"
                },
                {
                    "first": "Shmuel",
                    "initial": "S.",
                    "last": "Shoham"
                },
                {
                    "first": "Darin",
                    "initial": "D.",
                    "last": "Ostrander"
                },
                {
                    "first": "Terry",
                    "initial": "T.",
                    "last": "Woessner"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Thoman"
                },
                {
                    "first": "Jaime G.",
                    "initial": "J.G.",
                    "last": "Deville"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Lin"
                },
                {
                    "first": "Alyssa",
                    "initial": "A.",
                    "last": "Ziman"
                },
                {
                    "first": "Kavita",
                    "initial": "K.",
                    "last": "Shankar"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Feucht"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Blok"
                },
                {
                    "first": "Don",
                    "initial": "D.",
                    "last": "Batts"
                },
                {
                    "first": "Bob",
                    "initial": "B.",
                    "last": "Beck"
                },
                {
                    "first": "Gail",
                    "initial": "G.",
                    "last": "Massey"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Bradley"
                },
                {
                    "first": "Judith",
                    "initial": "J.",
                    "last": "Feinberg"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Carey"
                },
                {
                    "first": "Jenifer",
                    "initial": "J.",
                    "last": "Baer"
                },
                {
                    "first": "Eva Moore",
                    "initial": "E.M.",
                    "last": "Whitehead"
                },
                {
                    "first": "Sharon",
                    "initial": "S.",
                    "last": "Kohrs"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Giulitto"
                },
                {
                    "first": "Christina",
                    "initial": "C.",
                    "last": "Schofield"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Fairchok"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Chambers"
                },
                {
                    "first": "Cindy",
                    "initial": "C.",
                    "last": "Baker"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": "RN"
                },
                {
                    "first": "Michelle",
                    "initial": "M.",
                    "last": "Parker"
                },
                {
                    "first": "Marta",
                    "initial": "M.",
                    "last": "Harshbarger"
                },
                {
                    "first": "M. Hong",
                    "initial": "M.H.",
                    "last": "Nguyen"
                },
                {
                    "first": "Mary Ellen",
                    "initial": "M.E.",
                    "last": "Carey"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Paronish"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Cornell"
                },
                {
                    "first": "Jim",
                    "initial": "J.",
                    "last": "Cramer"
                },
                {
                    "first": "Diana Lynn",
                    "initial": "D.L.",
                    "last": "Pakstis"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Ison"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Wunderink"
                },
                {
                    "first": "Marshall",
                    "initial": "M.",
                    "last": "Glesby"
                },
                {
                    "first": "Kirsis",
                    "initial": "K.",
                    "last": "Ham"
                },
                {
                    "first": "Valery",
                    "initial": "V.",
                    "last": "Hughes"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Cushing"
                },
                {
                    "first": "Cheryl",
                    "initial": "C.",
                    "last": "Goss"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Grenade"
                },
                {
                    "first": "Pauline K.",
                    "initial": "P.K.",
                    "last": "Park"
                },
                {
                    "first": "Lena M.",
                    "initial": "L.M.",
                    "last": "Napolitano"
                },
                {
                    "first": "Krishnan",
                    "initial": "K.",
                    "last": "Raghavendran"
                },
                {
                    "first": "Robert C.",
                    "initial": "R.C.",
                    "last": "Hyzy"
                },
                {
                    "first": "Robertson",
                    "initial": "R.",
                    "last": "Davenport"
                },
                {
                    "first": "Kristin",
                    "initial": "K.",
                    "last": "Brierley"
                },
                {
                    "first": "Theresa",
                    "initial": "T.",
                    "last": "Downs"
                },
                {
                    "first": "Michelle Ng",
                    "initial": "M.N.",
                    "last": "Gong"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Uehlinger"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Lin"
                },
                {
                    "first": "Janice",
                    "initial": "J.",
                    "last": "Fritsche"
                },
                {
                    "first": "Tondria",
                    "initial": "T.",
                    "last": "Green"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "McLeod"
                },
                {
                    "first": "Deena",
                    "initial": "D.",
                    "last": "Patel"
                },
                {
                    "first": "Mary F.",
                    "initial": "M.F.",
                    "last": "Bavaro"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Deiss"
                },
                {
                    "first": "Carolyn",
                    "initial": "C.",
                    "last": "Brandt"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Cammarata"
                },
                {
                    "first": "Allan",
                    "initial": "A.",
                    "last": "Kremp"
                },
                {
                    "first": "Karine",
                    "initial": "K.",
                    "last": "Hollis-Perry"
                },
                {
                    "first": "Tahaniyat",
                    "initial": "T.",
                    "last": "Lalani"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Banks"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Johnson"
                },
                {
                    "first": "Jason",
                    "initial": "J.",
                    "last": "Maguire"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "McNiff"
                },
                {
                    "first": "Leslie E.",
                    "initial": "L.E.",
                    "last": "Rigg"
                },
                {
                    "first": "Anuradha",
                    "initial": "A.",
                    "last": "Ganesan"
                },
                {
                    "first": "Irma",
                    "initial": "I.",
                    "last": "Barahona"
                },
                {
                    "first": "Janine",
                    "initial": "J.",
                    "last": "Danko"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Spencer"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Stagliano"
                },
                {
                    "first": "Timothy",
                    "initial": "T.",
                    "last": "Burgess"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Talmor"
                },
                {
                    "first": "Monique",
                    "initial": "M.",
                    "last": "Mohammed"
                },
                {
                    "first": "Valerie",
                    "initial": "V.",
                    "last": "Banner-Goodspeed"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Salata"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Finberg"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Wang"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Longtine"
                },
                {
                    "first": "Jaclyn",
                    "initial": "J.",
                    "last": "Longtine"
                },
                {
                    "first": "Mellissa",
                    "initial": "M.",
                    "last": "O'Neil"
                },
                {
                    "first": "Philippe R.",
                    "initial": "P.R.",
                    "last": "Bauer"
                },
                {
                    "first": "Ognjen",
                    "initial": "O.",
                    "last": "Gajic"
                },
                {
                    "first": "Suanne M.",
                    "initial": "S.M.",
                    "last": "Weist"
                },
                {
                    "first": "Jonathan",
                    "initial": "J.",
                    "last": "Sevransky"
                },
                {
                    "first": "Mona",
                    "initial": "M.",
                    "last": "Brown"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Roback"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Oropello"
                },
                {
                    "first": "Bridget",
                    "initial": "B.",
                    "last": "Twohig"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Jhang"
                },
                {
                    "first": "Rahgu",
                    "initial": "R.",
                    "last": "Seethala"
                },
                {
                    "first": "Wilbur H.",
                    "initial": "W.H.",
                    "last": "Chen"
                },
                {
                    "first": "Magali",
                    "initial": "M.",
                    "last": "Fontaine"
                },
                {
                    "first": "Kapil",
                    "initial": "K.",
                    "last": "Saharia"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Husson"
                },
                {
                    "first": "Roberta",
                    "initial": "R.",
                    "last": "DeBiasi"
                },
                {
                    "first": "Jurran L.",
                    "initial": "J.L.",
                    "last": "Wilson"
                },
                {
                    "first": "Valli Ree",
                    "initial": "V.R.",
                    "last": "Criss"
                },
                {
                    "first": "Jocelyn",
                    "initial": "J.",
                    "last": "Voell"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Leitman"
                },
                {
                    "first": "James Wade",
                    "initial": "J.W.",
                    "last": "Atkins"
                },
                {
                    "first": "Hemaxi",
                    "initial": "H.",
                    "last": "Patel"
                },
                {
                    "first": "Traci",
                    "initial": "T.",
                    "last": "Paige"
                },
                {
                    "first": "Cathy",
                    "initial": "C.",
                    "last": "Cantilena"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/S2213-2600(17)30174-1",
            "firstpage": "500",
            "issn": "22132600",
            "lastpage": "511",
            "pmid": "28522352",
            "pub_year": 2017,
            "title": "Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study",
            "volume": "5"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Ben",
                    "initial": "B.",
                    "last": "Killingley"
                },
                {
                    "first": "Joanne E.",
                    "initial": "J.E.",
                    "last": "Enstone"
                },
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Greatorex"
                },
                {
                    "first": "Anthony S.",
                    "initial": "A.S.",
                    "last": "Gilbert"
                },
                {
                    "first": "Rob",
                    "initial": "R.",
                    "last": "Lambkin-Williams"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Cauchemez"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Katz"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Booy"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Hayward"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Oxford"
                },
                {
                    "first": "Carolyn B.",
                    "initial": "C.B.",
                    "last": "Bridges"
                },
                {
                    "first": "Neil M.",
                    "initial": "N.M.",
                    "last": "Ferguson"
                },
                {
                    "first": "Jonathan S.Nguyen",
                    "initial": "J.S.N.",
                    "last": "Van-Tam"
                }
            ],
            "doi": "10.1093/infdis/jir701",
            "firstpage": "35",
            "issn": "00221899",
            "lastpage": "43",
            "pmid": "22131338",
            "pub_year": 2012,
            "title": "Use of a human influenza challenge model to assess person-to-person transmission: Proof-of-concept study",
            "volume": "205"
        },
        "b0125": null,
        "b0130": null,
        "b0135": {
            "authors": [
                {
                    "first": "Alison",
                    "initial": "A.",
                    "last": "Han"
                },
                {
                    "first": "Jiat Ling",
                    "initial": "J.L.",
                    "last": "Poon"
                },
                {
                    "first": "John H.",
                    "initial": "J.H.",
                    "last": "Powers"
                },
                {
                    "first": "Nancy K.",
                    "initial": "N.K.",
                    "last": "Leidy"
                },
                {
                    "first": "Ren",
                    "initial": "R.",
                    "last": "Yu"
                },
                {
                    "first": "Matthew J.",
                    "initial": "M.J.",
                    "last": "Memoli"
                }
            ],
            "doi": "10.1186/s12879-018-3220-8",
            "issn": "14712334",
            "pmid": "30055573",
            "pub_year": 2018,
            "title": "Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model",
            "volume": "18"
        }
    },
    "body_text": [
        {
            "endOffset": 23416,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "An example of planning for unforeseen risk might include limiting study size to ensure adequate duty of care is available in the event of multiple SAEs.",
            "startOffset": 23264,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 12323,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "However, a young healthy cohort does not well represent the immune compromise associated with high-risk groups such as infants, pregnant women, and elderly adults.",
            "startOffset": 12160,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 15765,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In field trials of influenza vaccines, efficacy is generally higher against moderate to severe disease and lower against mild disease.",
            "startOffset": 15631,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 27405,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The panel also discussed the optimal timing for conducting challenge trials in relation to seasonal influenza patterns.",
            "startOffset": 27286,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 17626,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Several devices have been developed for delivering viral challenge to the respiratory tract.",
            "startOffset": 17534,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 11392,
            "parents": [],
            "secId": "s0005",
            "sentence": "Recommendations reflect a \u201cmajority report\u201d with panelists\u2019 recommendations, as reflected in their slides and comments from the dais, and comments from the audience being reported.",
            "startOffset": 11212,
            "title": "Introduction"
        },
        {
            "endOffset": 27905,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "With careful isolation/containment procedures, it is possible to conduct HCTs during influenza season.",
            "startOffset": 27803,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 28048,
            "parents": [],
            "secId": "s0050",
            "sentence": "Several gaps were identified that should be addressed in order to make CHIVIM a more effective tool for influenza vaccine research:",
            "startOffset": 27917,
            "title": "Conclusions"
        },
        {
            "endOffset": 15630,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 15629,
                    "startOffset": 15624
                },
                "b0035": {
                    "endOffset": 15629,
                    "startOffset": 15624
                },
                "b0040": {
                    "endOffset": 15629,
                    "startOffset": 15624
                },
                "b0045": {
                    "endOffset": 15629,
                    "startOffset": 15624
                }
            },
            "secId": "s0020",
            "sentence": "HCTs that expose a participant to influenza virus via the intranasal route are able to assess protection against upper respiratory illness, but less so against lower respiratory illness, which is an infrequent outcome of current challenge models [6\u20139].",
            "startOffset": 15378,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 20439,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 20438,
                    "startOffset": 20434
                }
            },
            "secId": "s0030",
            "sentence": "Pimodivir has been shown to be effective in combination with oseltamivir [19].",
            "startOffset": 20361,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 15241,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Another concern regarding aerosol delivery is that the virus may bypass immune defenses in the upper respiratory tract that are important to vaccine efficacy.",
            "startOffset": 15083,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 12558,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Rather than screening out participants who have pre-existing immunity to influenza (high hemagglutination inhibition (HI) titers), it may be preferable to do extensive baseline testing for multiple indicators of pre-existing immunity.",
            "startOffset": 12324,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 24193,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "It was noted that reverse barrier (protective isolation) infectious disease controls are effective.",
            "startOffset": 24094,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 14350,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "However, including participants with pre-existing immunity can result in lower attack rates, leading to compromised efficacy evaluations.",
            "startOffset": 14213,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 11211,
            "parents": [],
            "secId": "s0005",
            "sentence": "The authors would like to thank the following panelists who shared their experience and best practices in CHIVIM Methods: Rebecca Jane Cox PhD, University of Bergen Influenza Centre; John Oxford, PhD, Queen Mary College; Gene Saxon, MEng, MME, PATH; Mark Papania MD, CDC; Frederick Hayden, MD, University of Virginia School of Medicine; Adrian Wildfire, MSc, SGS Life Sciences; and Donald Milton, MD, DrPH, University of Maryland School of Public Health.",
            "startOffset": 10757,
            "title": "Introduction"
        },
        {
            "endOffset": 20631,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Antibody-based therapies are in development as well.",
            "startOffset": 20579,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 18822,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 18821,
                    "startOffset": 18817
                }
            },
            "secId": "s0025",
            "sentence": "Mesh nebulizers have been used to deliver live attenuated influenza vaccine in ferrets and are being studied as part of the World Health Organization Measles Aerosol Project [15].",
            "startOffset": 18643,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 25614,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "There was one transmission by droplet nuclei in the US study, and no evidence of transmission by direct contact or large droplet spray.",
            "startOffset": 25479,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 27069,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Specimen sampling and safety constraints can limit the feasibility of managing larger numbers.",
            "startOffset": 26975,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 14062,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Screening for baseline pulmonary function and airway hyperactivity may be useful for reducing participant risk (see Rescue Therapy).",
            "startOffset": 13930,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 18313,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "These inhalers are widely used for asthma medication, and the dosing is simpler but less precise than with nasal powders.",
            "startOffset": 18192,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 24376,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Vaccination, antiviral prophylaxis, medical monitoring and diagnostic testing are other possible protective measures.",
            "startOffset": 24259,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 13827,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Important participant screening information includes age, influenza illness and vaccine history.",
            "startOffset": 13731,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 15919,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Thus, if a vaccine can prevent mild disease in a challenge setting, it could be argued to have potential to prevent more severe disease in a field trial.",
            "startOffset": 15766,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 26835,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Immunocompromised or elderly adults can have no fever but still go on to experience severe complications of influenza virus infection.",
            "startOffset": 26701,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 22708,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 22606,
                    "startOffset": 22602
                }
            },
            "secId": "s0035",
            "sentence": "Tools such as the National Institute for Health Research Clinical Trials Toolkit [25] can be used to define specific risks associated with a trial and determine how they can be mitigated.",
            "startOffset": 22521,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 16076,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0050": {
                    "endOffset": 16075,
                    "startOffset": 16071
                }
            },
            "secId": "s0020",
            "sentence": "The Common Cold Unit (Salisbury UK) conducted influenza challenge trials for over forty years using intranasal delivery with an excellent safety record [10].",
            "startOffset": 15919,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 25478,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A similar study performed in the United States increased the number of donors and days of exposure, but there was no aerosol transmission observed, which may have been due to the presence of ventilation.",
            "startOffset": 25275,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 26213,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Sequencing of specimens collected from participants by nasopharyngeal swab and aerosol particle collection revealed 59 single nucleotide polymorphism differences between samples from the nose and from the lung.",
            "startOffset": 26003,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 18191,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "For pulmonary challenge, dry powder inhalers can deliver small (<5 \u00b5m) particles to alveoli with one or two breaths.",
            "startOffset": 18075,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 26455,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0135": {
                    "endOffset": 26366,
                    "startOffset": 26362
                }
            },
            "secId": "s0040",
            "sentence": "The Influenza Patient-recorded Outcome diary (Flu-Pro) [27] is another tool that can be used to measure clinical outcomes after influenza challenge.",
            "startOffset": 26307,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 15082,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0010": {
                    "endOffset": 14921,
                    "startOffset": 14918
                },
                "b0015": {
                    "endOffset": 15081,
                    "startOffset": 15076
                },
                "b0020": {
                    "endOffset": 15081,
                    "startOffset": 15076
                },
                "b0025": {
                    "endOffset": 15081,
                    "startOffset": 15076
                },
                "b0030": {
                    "endOffset": 15081,
                    "startOffset": 15076
                },
                "b0035": {
                    "endOffset": 15081,
                    "startOffset": 15076
                }
            },
            "secId": "s0020",
            "sentence": "As discussed in Part 1 [2], aerosol delivery produces disease that better represents natural infection, but increases the risk of severe disease complications in study participants [3\u20137].",
            "startOffset": 14895,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 19368,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Baseline screening tests for safety should include tests of pulmonary function, oxygen saturation, chest X-rays/CT, and testing for concurrent respiratory viral infections.",
            "startOffset": 19196,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 17326,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Before aerosol challenge can be proposed, a delivery device that controls release of virus into the environment must be developed and validated, and clinical experts should endorse a protocol for prompt initiation of rescue therapy in trial participants attaining a defined clinical endpoint (see below).",
            "startOffset": 17022,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 29231,
            "parents": [],
            "secId": "s0050",
            "sentence": "Nasal atomizer is recommended for delivery of challenge, based on safety, variable particle size, larger surface area delivery, and participant comfort",
            "startOffset": 29080,
            "title": "Conclusions"
        },
        {
            "endOffset": 11504,
            "parents": [],
            "secId": "s0005",
            "sentence": "All panelists and participants had the opportunity to review and comment on a late draft of the meeting report.",
            "startOffset": 11393,
            "title": "Introduction"
        },
        {
            "endOffset": 15377,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Intranasal droplet challenge has a demonstrated history of safety and shows less dose variability but elicits milder clinical symptoms.",
            "startOffset": 15242,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 25155,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "These studies placed experimentally infected donors in a sealed room with recipients to measure aerosol transmission.",
            "startOffset": 25038,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 21740,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Influenza challenge trials performed with virus inoculation by the intranasal route in the past 50 years have had good safety records with few unexpected serious adverse events (SAEs).",
            "startOffset": 21556,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 22520,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 22348,
                    "startOffset": 22344
                }
            },
            "secId": "s0035",
            "sentence": "Known risks associated with challenge trials include SAEs, onward transmission from study participants [24], uncontrolled release, as well as more general risk associated with clinical trials such as failure in duty of care, negligence, procedural/equipment failure, or sabotage.",
            "startOffset": 22241,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 13929,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Screening could be tailored to the mode of action of the vaccine being studied in a particular trial.",
            "startOffset": 13828,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 27185,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Larger studies may be necessary to attain adequate power, so the enrollment of sequential cohorts may be necessary.",
            "startOffset": 27070,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 13452,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Careful characterization of pre-challenge immunity is essential for comprehensive explanation of challenge outcomes, leading to better predictions about the efficacy of vaccine candidates in at-risk populations.",
            "startOffset": 13241,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 13730,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "To fully characterize pre-existing immunity of CHIVIM study participants, useful assays include HI, microneutralization, neuraminidase (NA) inhibition, single-radial-hemolysis, stalk-specific antibodies, nasal IgA, IFNgamma ELISpot, T cell flow cytometry, and functional assays.",
            "startOffset": 13452,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 26974,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The average size for respiratory challenge trials requiring containment is about fifty participants.",
            "startOffset": 26874,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 29313,
            "parents": [],
            "secId": "s0050",
            "sentence": "Rescue therapy intervention should be available for participants to minimize risk",
            "startOffset": 29232,
            "title": "Conclusions"
        },
        {
            "endOffset": 28656,
            "parents": [],
            "secId": "s0050",
            "sentence": "Screen for healthy adult study participants and exclude those who are at-risk for severe illness, smokers, and participants with respiratory virus infections",
            "startOffset": 28499,
            "title": "Conclusions"
        },
        {
            "endOffset": 16383,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0055": {
                    "endOffset": 16382,
                    "startOffset": 16378
                }
            },
            "secId": "s0020",
            "sentence": "After optimized intranasal delivery of diluted virus solution droplets, technetium-enabled studies showed widespread exposure to challenge throughout the respiratory tract [11].",
            "startOffset": 16206,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 24093,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The panel discussion included possible protective measures for the staff conducting the study.",
            "startOffset": 23999,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 23263,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "A similar list could be developed with methods for protecting against risks related to challenge trials, such as reviewing study design (following known guidelines and seeking independent expert advice), careful risk/benefit analysis, prescreening, proper documentation (informed consent and qualifications of investigators), rigorous trial monitoring, insurance protection, and periodic reappraisal of the safety plan.",
            "startOffset": 22844,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 22152,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Changes to the challenge model to increase the frequency or intensity of illness (e.g., virus strain or method of administration) should be done incrementally, with caution, and only if essential.",
            "startOffset": 21956,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 19787,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Participants should be closely monitored for signs of severe illness such as shortness of breath, wheezing, and severe cough.",
            "startOffset": 19662,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 18074,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 18073,
                    "startOffset": 18069
                }
            },
            "secId": "s0025",
            "sentence": "Intranasal liquid challenge results in a short residence time, and the target delivery area is relatively small (150 cm2) compared to aerosol delivery (estimated total lung surface area is between 50 and 75 square meters) [14].",
            "startOffset": 17847,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 27802,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The advantages of conducting HCTs outside of influenza season were weighed against practical concerns, such as the problem of having to interrupt longer duration trials and the fact that recruitment is often easier during student holidays.",
            "startOffset": 27563,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 26700,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Naturally infected adults often remain afebrile, but fever correlates with disease severity in children.",
            "startOffset": 26596,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 14212,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A more inclusive screening strategy reduces the need for extensive participant recruitment and expense and helps prevent selection of a skewed cohort.",
            "startOffset": 14062,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 20067,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Other recommended monitoring methods include frequent checks of vital signs, viral shedding (using rapid diagnostic tests), biomarkers for bacterial infection, peak expiratory flow rate measurements, spirometry, EKG, echocardiogram, cardiac enzymes, and chest X-ray/CT as needed.",
            "startOffset": 19788,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 25788,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A dynamic breath catcher was used to catch and measure aerosol viral particles from donor participants who had received intranasal viral challenge (H3N2 A/Wisconsin/67/2005).",
            "startOffset": 25614,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 28390,
            "parents": [],
            "secId": "s0050",
            "sentence": "Challenge trials can only evaluate reduction in virus shedding and (mild to moderate) symptom intensity; severe disease cannot be modeled",
            "startOffset": 28253,
            "title": "Conclusions"
        },
        {
            "endOffset": 14833,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "When discussing route of exposure for challenge virus, the central focus of debate centered around the tension between assessing vaccine efficacy against severe disease and safety concerns associated with aerosol challenge delivery.",
            "startOffset": 14601,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 29079,
            "parents": [],
            "secId": "s0050",
            "sentence": "Empirically establish effective dose for each new challenge strain in a dose escalation trial",
            "startOffset": 28986,
            "title": "Conclusions"
        },
        {
            "endOffset": 20842,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0115": {
                    "endOffset": 20841,
                    "startOffset": 20837
                }
            },
            "secId": "s0030",
            "sentence": "Intravenous anti-influenza immune plasma combined with oseltamivir tended to shorten respiratory function recovery time and reduce mortality from severe influenza A infection compared to oseltamivir alone [23].",
            "startOffset": 20632,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 20286,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 20251,
                    "startOffset": 20247
                }
            },
            "secId": "s0030",
            "sentence": "Current influenza therapies include adamantanes (e.g. rimantadine), NA inhibitors (e.g. oseltamivir), and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil [17], as well as combinations of these.",
            "startOffset": 20067,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 23708,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Designing safe challenge viruses (discussed above) is an important step for mitigating risk.",
            "startOffset": 23616,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 21168,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "However, one recent randomized controlled trial (RCT) testing high doses of the anti-HA stem antibody MHAA4549A combined with oseltamivir (NCT02293863) and another RCT testing hyperimmune globulin combined with a NA inhibitor (NCT02287467) did not show superiority over oseltamivir alone in hospitalized influenza A patients.",
            "startOffset": 20843,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 17496,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Whereas aerosol delivery may better simulate severe lower respiratory infections, the risks should be carefully evaluated and should not outweigh the potential benefits.",
            "startOffset": 17327,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 29805,
            "parents": [],
            "secId": "s0050",
            "sentence": "The risks of using aerosol challenge are significant; such studies should be deferred until an appropriate delivery device is developed and validated, a rescue therapy protocol is available, and there is assurance of significant public health benefits that would justify risk.",
            "startOffset": 29529,
            "title": "Conclusions"
        },
        {
            "endOffset": 14572,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "High-dose challenge was discussed as a means of increasing attack rate, but the immunologic response to such a challenge may not be as physiologically meaningful and high-dose challenges can overwhelm the immune response.",
            "startOffset": 14351,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 26595,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Panelists discussed the lack of proxy measures for severe disease with experimentally induced influenza.",
            "startOffset": 26491,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 28204,
            "parents": [],
            "secId": "s0050",
            "sentence": "Need standardization of delivery devices and standard operating procedures for optimal delivery",
            "startOffset": 28109,
            "title": "Conclusions"
        },
        {
            "endOffset": 23838,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Animal studies and dose-escalation first-in-human trials can provide important safety data and evidence of virulence/attack rate.",
            "startOffset": 23709,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 24492,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Staff should also be screened when entering and leaving wards to prevent introduction of outside infectious agents.",
            "startOffset": 24377,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 18642,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Vibrating mesh nebulizer systems can dose more efficiently with desired particle size, don\u2019t require air flow, and are currently licensed for asthma medication.",
            "startOffset": 18482,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 13101,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "HI is the most widely used screening assay, though screening participants for low HI titers to increase attack rates was highlighted at the meeting as a possible bias, as this practice might enrich the challenge group with generally poor responders to influenza.",
            "startOffset": 12839,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 29867,
            "parents": [],
            "secId": "s0050",
            "sentence": "All authors attest they meet the ICMJE criteria for authorship",
            "startOffset": 29805,
            "title": "Conclusions"
        },
        {
            "endOffset": 17758,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The ideal device would reliably deliver a consistent dose to desired target areas, with low risk of environmental escape (Table 2).",
            "startOffset": 17627,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 19195,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Screening for healthy adult study participants (<45 years) and excluding all at-risk groups listed by the CDC as well as current/recent cigarette smokers is recommended.",
            "startOffset": 19026,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 10448,
            "parents": [],
            "secId": "s0005",
            "sentence": "This report (in two parts) summarizes those discussions and offers recommendations to improve CHIVIM as a necessary tool for universal influenza vaccine development.",
            "startOffset": 10283,
            "title": "Introduction"
        },
        {
            "endOffset": 12839,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0005": {
                    "endOffset": 12631,
                    "startOffset": 12628
                }
            },
            "secId": "s0015",
            "sentence": "This information could help identify correlates of protection (CoPs) [1] (markers of immune function that statistically correlate with protection after vaccination) which could then predict whether immune responses attained in at-risk groups were likely to offer clinical benefit.",
            "startOffset": 12559,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 27286,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Flexibility with timing of administering vaccine and challenge can help prevent participant dropout.",
            "startOffset": 27186,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 10068,
            "parents": [],
            "secId": "s0005",
            "sentence": "Participants included vaccine researchers, public health officials, regulatory experts, and representatives from the pharmaceutical industry.",
            "startOffset": 9927,
            "title": "Introduction"
        },
        {
            "endOffset": 10756,
            "parents": [],
            "secId": "s0005",
            "sentence": "This article (Part 2) summarizes discussion and recommendations related to CHIVIM methods, including study participant selection and screening, route of exposure and dose, devices for administering challenge, rescue therapy, protection of participants and institutions, and other methodologic considerations.",
            "startOffset": 10448,
            "title": "Introduction"
        },
        {
            "endOffset": 19512,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Genetic susceptibility, upper respiratory tract bacterial pathogens, and low influenza cellular immunity are other possible screening criteria.",
            "startOffset": 19369,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 19662,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 19661,
                    "startOffset": 19657
                }
            },
            "secId": "s0030",
            "sentence": "Subclinical cardiac abnormalities have been associated with influenza, so baseline electrocardiography (EKG) or echocardiogram may be warranted [16].",
            "startOffset": 19513,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 20578,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 20577,
                    "startOffset": 20570
                },
                "b0105": {
                    "endOffset": 20577,
                    "startOffset": 20570
                },
                "b0110": {
                    "endOffset": 20577,
                    "startOffset": 20570
                }
            },
            "secId": "s0030",
            "sentence": "NA inhibitor treatment reduces hospitalization and mortality from severe H1N1 influenza if given within 4\u20135 days of illness onset [20\u201322].",
            "startOffset": 20440,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 28252,
            "parents": [],
            "secId": "s0050",
            "sentence": "Need for agreement on standard rescue protocols",
            "startOffset": 28205,
            "title": "Conclusions"
        },
        {
            "endOffset": 29395,
            "parents": [],
            "secId": "s0050",
            "sentence": "Rescue therapy should combine two treatment agents with different modes of action",
            "startOffset": 29314,
            "title": "Conclusions"
        },
        {
            "endOffset": 14894,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Current influenza challenge models use the intranasal route.",
            "startOffset": 14834,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 21504,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Careful screening and monitoring of participants, selecting (or developing) challenge viruses that are sensitive to antiviral therapy, and early rescue therapy intervention (as soon as endpoints are reached) with a combination of two agents (using different modes of action) can reduce the risk of severe complications in CHIVIM trials.",
            "startOffset": 21168,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 28108,
            "parents": [],
            "secId": "s0050",
            "sentence": "Need to determine appropriate ranges for screening criteria",
            "startOffset": 28049,
            "title": "Conclusions"
        },
        {
            "endOffset": 24709,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "One potential use for influenza challenge trials is for modeling disease transmission to evaluate the effect of potential vaccines on transmission rates.",
            "startOffset": 24556,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 26002,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "These participants had lower levels of viral shedding (one log lower than average measurements from community-acquired infection), and less variability in particle size compared to naturally infected participants.",
            "startOffset": 25789,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 19025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Reducing the risk of severe illness during influenza challenge trials is a multi-approach strategy that includes pre-screening, careful monitoring, and appropriate use of rescue therapy.",
            "startOffset": 18839,
            "title": "Rescue therapy"
        },
        {
            "endOffset": 16205,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "In lieu of pre-screening for pre-immunity, healthy participants were stratified into categories according to baseline HI titers.",
            "startOffset": 16077,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 16681,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 16680,
                    "startOffset": 16676
                }
            },
            "secId": "s0020",
            "sentence": "Infections occurred only in participants with low or absent neutralizing antibody titers [12].",
            "startOffset": 16587,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 9926,
            "parents": [],
            "secId": "s0005",
            "sentence": "The Bill & Melinda Gates Foundation, PATH and the Global Funders Consortium for Universal Influenza Vaccine Development convened a meeting of approximately 60 experts in London, UK (May 31\u2013June 1, 2018) to collect perspectives and identify best practices on how to improve the utility of a standardized controlled human influenza virus infection model (CHIVIM) as a tool for development and evaluation of novel universal vaccines.",
            "startOffset": 9496,
            "title": "Introduction"
        },
        {
            "endOffset": 28498,
            "parents": [],
            "secId": "s0050",
            "sentence": "The panel agreed on the following recommendations for improving and standardizing the methodology of CHIVIM:",
            "startOffset": 28390,
            "title": "Conclusions"
        },
        {
            "endOffset": 10153,
            "parents": [],
            "secId": "s0005",
            "sentence": "The meeting focused on five topics, each with a set of critical pragmatic questions.",
            "startOffset": 10069,
            "title": "Introduction"
        },
        {
            "endOffset": 10282,
            "parents": [],
            "secId": "s0005",
            "sentence": "Leaders in the field chaired each session and moderated discussion panels to address the questions in depth with audience input.",
            "startOffset": 10154,
            "title": "Introduction"
        },
        {
            "endOffset": 23999,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Good manufacturing process (GMP) can increase safety, although currently there is no guidance available that is specific to the production of challenge viruses.",
            "startOffset": 23839,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 16586,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "A 1966 aerosol inhalational challenge trial with a low-dose of an H2 strain (3-TCID50 (50% Tissue Culture Infectious Dose)) induced typical influenza disease in a small number of non-immune participants.",
            "startOffset": 16383,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 23616,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "CHIVIM sponsors should ensure that their insurance policy covers both negligent harm to trial participants and non-negligent harm (no-fault compensation) and should be aware of their coverage limits.",
            "startOffset": 23417,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 25274,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "One study in the United Kingdom achieved a 25% attack rate with two days of exposure in a room with recirculating air.",
            "startOffset": 25156,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 16795,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 16794,
                    "startOffset": 16790
                }
            },
            "secId": "s0020",
            "sentence": "Another trial using intranasal challenge required 50\u2013100 times that dose of H3N2 to achieve the same effect [13].",
            "startOffset": 16682,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 22240,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Careful risk evaluation should include consideration of both known and unforeseen risks.",
            "startOffset": 22152,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 22843,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 22752,
                    "startOffset": 22748
                }
            },
            "secId": "s0035",
            "sentence": "The \u201c8P\u2019s of Protection\u201d screening tool [26] is used to assess risk for adverse events after a patient is discharged from the hospital.",
            "startOffset": 22708,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 25038,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 24796,
                    "startOffset": 24792
                }
            },
            "secId": "s0040",
            "sentence": "The Centers for Disease Control EMIT (Evaluating Modes of Influenza Transmission) [24] studies, which were designed to evaluate the contribution of aerosols to influenza transmission, provide some insight into how challenge models can be used to elicit better understanding of the transmission factors associated with influenza.",
            "startOffset": 24710,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 26873,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The issue of study size was addressed.",
            "startOffset": 26835,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 11942,
            "parents": [],
            "secId": "s0005",
            "sentence": "The companion article \u201cMeeting Report: Convening on the Influenza Human Viral Challenge Model for Universal Influenza Vaccine, Part 1\u201d covers the other topics discussed at the meeting, including realizing the full value of CHIVIM, selection of challenge virus strains, industry and regulatory perspectives, ethical considerations, standardization, and increasing capacity and access, as well as the complete list of meeting participants.",
            "startOffset": 11505,
            "title": "Introduction"
        },
        {
            "endOffset": 29528,
            "parents": [],
            "secId": "s0050",
            "sentence": "A careful risk evaluation should be performed before any challenge trial, including consideration of both known and unforeseen risks",
            "startOffset": 29396,
            "title": "Conclusions"
        },
        {
            "endOffset": 17846,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Nasal delivery is simple and low risk, but the administered dose can be highly variable.",
            "startOffset": 17758,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 26307,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The results suggest that route of infection may play a significant role in influenza disease.",
            "startOffset": 26214,
            "title": "Clinical outcome measures in experimentally induced influenza"
        },
        {
            "endOffset": 24258,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Personal protective equipment for clinical staff is recommended.",
            "startOffset": 24194,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 27562,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The potential for possible exposure to naturally circulating virus during the period of time between vaccination and challenge must be carefully considered.",
            "startOffset": 27406,
            "title": "Other methodologic considerations"
        },
        {
            "endOffset": 28985,
            "parents": [],
            "secId": "s0050",
            "sentence": "To balance ease of enrollment versus minimizing variability between subjects, it was suggested not to screen out all participants with pre-existing immunity (high HI titers) but instead perform thorough baseline characterization of immunity (CoPs) and balance immunity profiles of each trial\u2019s treatment groups by stratification",
            "startOffset": 28657,
            "title": "Conclusions"
        },
        {
            "endOffset": 12159,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "When selecting participants for human challenge trials (HCTs), screening for healthy young adults reduces the risk of complications related to severe disease.",
            "startOffset": 12001,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 18481,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Liquid aerosol devices can deliver small particles (<5 \u00b5m) to the alveoli but require time to administer with significant risk of virus escaping to the lab environment.",
            "startOffset": 18313,
            "title": "Devices for administering challenge"
        },
        {
            "endOffset": 17021,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Modeling lower respiratory infection via aerosolized challenge may be useful for universal vaccine development, though panelists noted that most cases of community-acquired influenza are limited to the upper respiratory tract.",
            "startOffset": 16795,
            "title": "Route of exposure and dose"
        },
        {
            "endOffset": 13240,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0015",
            "sentence": "There are many other potential immune markers (Table 1), and CHIVIM studies provide the opportunity to further explore these correlations.",
            "startOffset": 13102,
            "title": "Study participant selection and screening"
        },
        {
            "endOffset": 21955,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Although the potential of influenza challenge trials to accelerate development of broadly protective influenza vaccines was acknowledged at this meeting, the participants agreed that safety was a paramount concern.",
            "startOffset": 21741,
            "title": "Protection of study participants and institutions"
        },
        {
            "endOffset": 20360,
            "parents": [
                {
                    "id": "s0010",
                    "title": "CHIVIM methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 20359,
                    "startOffset": 20355
                }
            },
            "secId": "s0030",
            "sentence": "Favipiravir and pimodivir are investigational polymerase inhibitors [18].",
            "startOffset": 20287,
            "title": "Rescue therapy"
        }
    ],
    "docId": "S0264410X19308151",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "binnis@path.org",
                "first": "Bruce L.",
                "initial": "B.L.",
                "last": "Innis"
            },
            {
                "email": "fberlanda-scorza@path.org",
                "first": "Francesco Berlanda",
                "initial": "F.B.",
                "last": "Scorza"
            },
            {
                "email": "Jeremy.Blum@gatesfoundation.org",
                "first": "Jeremy S.",
                "initial": "J.S.",
                "last": "Blum"
            },
            {
                "email": null,
                "first": "Varsha K.",
                "initial": "V.K.",
                "last": "Jain"
            },
            {
                "email": "Anastazia.OlderAguilar@gatesfoundation.org",
                "first": "Anastazia Older",
                "initial": "A.O.",
                "last": "Aguilar"
            },
            {
                "email": "postd@niaid.nih.gov",
                "first": "Diane J.",
                "initial": "D.J.",
                "last": "Post"
            },
            {
                "email": "paul.roberts@nih.gov",
                "first": "Paul C.",
                "initial": "P.C.",
                "last": "Roberts"
            },
            {
                "email": null,
                "first": "Niteen",
                "initial": "N.",
                "last": "Wairagkar"
            },
            {
                "email": "Janet.White@gatesfoundation.org",
                "first": "J.",
                "initial": "J.",
                "last": "White"
            },
            {
                "email": "jbresee@taskforce.org",
                "first": "Joseph",
                "initial": "J.",
                "last": "Bresee"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.06.053",
        "firstpage": "4830",
        "issn": "0264410X",
        "keywords": [
            "Human challenge trial",
            "Influenza",
            "Influenza vaccine",
            "Research methods",
            "Universal vaccine"
        ],
        "lastpage": "4834",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations"
    }
}